PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay

导出原文传递

翻译打印收藏纠错

作者： Sakamoto, Yasunari ^[1] ; Yamagishi, Seri ^[2] ; Tanizawa, Yoshinori ^[3] ; Tajimi, Masaomi ; Okusaka, Takuji ; Ojima, Hidenori

作者单位： Eli Lilly Japan, Med Dev Unit Japan, Kobe, Hyogo, Japan ^[1] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan ^[2] Natl Canc Ctr, Div Canc Genom, Tokyo, Japan ^[3]

关键词 biliary tract cancer phosphatidylinositol 3-kinases TOR serine-threonine kinases drug resistance neoplasm drug screening assays antitumor

发布时间 2019-02-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Japanese journal of clinical oncology.

2018年48卷4期

396-399页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay

Japanese journal of clinical oncology.

相似文献

Japanese journal of clinical oncology.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay

Japanese journal of clinical oncology.

相似文献

Japanese journal of clinical oncology.

相关期刊

检索历史清除